PT  - JOURNAL ARTICLE
AU  - Cunningham, Muriel
TI  - Bifeprunox: Efficacy with Minimal Metabolic Concerns
DP  - 2007 Aug 01
TA  - MD Conference Express
PG  - 13--13
VI  - 7
IP  - 2
4099  - http://mdc.sagepub.com/content/7/2/13.short
4100  - http://mdc.sagepub.com/content/7/2/13.full
AB  - Bifeprunox, a partial dopamine agonist, is being developed as a possible treatment for schizophrenia. The results of a 6-month randomized, double-blind, placebo-controlled study of 497 patients with schizophrenia.